Instil Bio Inc (TIL)

$28.53 -1.31 (-4.39%)
Market Cap 195.72M
Revenue (ttm) 0.00
Net Income (ttm) -74.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.58
Volume 211,400
Avg Vol 313,732
Day's Range N/A - N/A
Shares Out 6.56M
Stochastic %K 17%
Beta 2.26
Analysts Strong Sell
Price Target $118.67

Company Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 499 3350
Address:
3963 Maple Avenue, Suite 350, Dallas, United States
Doozio
Doozio Jun. 24 at 4:41 AM
Wait $TIL Roger see’s that comp rating to da monthly
0 · Reply
deezycvsh
deezycvsh Jun. 13 at 3:06 PM
$TIL What happened to this stock today
1 · Reply
Bigmal1
Bigmal1 Jun. 11 at 2:40 PM
$TIL institutions must be loading at the volume it’s been going
1 · Reply
_www_larval_com_
_www_larval_com_ Jun. 10 at 7:57 PM
$BIYA -8%[-48%] $EDHL 5%[10%] $BIRD -4%[20%] $TGE 4%[-9%] $TIL -3%[7%] most notable movement into the final minutes of trading.
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 5:22 PM
$TIL Keep going and split this stock!
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 4:49 PM
$TIL Oh now thats a tingle....
0 · Reply
BlakeCanyon50
BlakeCanyon50 Jun. 10 at 3:57 PM
$TIL +32% Later
1 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 1:02 PM
$TIL Needs to be north of $40 for me to take seriously!!!
1 · Reply
Bigmal1
Bigmal1 Jun. 9 at 2:28 PM
$TIL get through $35 and we see $100
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 7 at 1:32 PM
$TIL $GLYC ticker will change to CBIO with approx 25M fd shares OS at $20PS. Double the market cap of $TIL
0 · Reply
Latest News on TIL
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Jun 11, 2025, 7:00 AM EDT - 14 days ago

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Jun 2, 2025, 7:00 AM EDT - 23 days ago

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 26 days ago

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025, 7:09 AM EDT - 4 weeks ago

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025, 7:00 AM EDT - 4 weeks ago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 22, 2025, 6:00 AM EDT - 4 weeks ago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 7:00 AM EDT - 6 weeks ago

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 4, 2025, 7:09 AM EST - 4 months ago

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Jan 14, 2025, 7:00 AM EST - 5 months ago

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Jan 7, 2025, 2:06 PM EST - 6 months ago

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Dec 1, 2024, 5:00 AM EST - 7 months ago

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Sep 16, 2024, 12:31 PM EDT - 10 months ago

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Sep 16, 2024, 6:00 AM EDT - 10 months ago

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Sep 13, 2024, 1:22 PM EDT - 10 months ago

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 5:00 PM EDT - 11 months ago

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Aug 1, 2024, 6:00 AM EDT - 11 months ago

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 7:00 AM EDT - 1 year ago

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 5:00 PM EDT - 1 year ago

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil Bio Announces Strategic Update

Jan 16, 2024, 8:00 AM EST - 1 year ago

Instil Bio Announces Strategic Update

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

Dec 5, 2023, 5:00 PM EST - 1 year ago

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 5:00 PM EST - 1 year ago

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Nov 6, 2023, 7:00 AM EST - 1 year ago

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Jun 26, 2023, 4:38 PM EDT - 2 years ago

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 31, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Jan 31, 2023, 5:00 PM EST - 2 years ago

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

7 Cheap But Risky Biotech Stocks

Jan 18, 2023, 1:58 PM EST - 2 years ago

7 Cheap But Risky Biotech Stocks

BCAB IMRX NKTX

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Jan 9, 2023, 7:00 AM EST - 2 years ago

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Dec 12, 2022, 11:45 AM EST - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Dec 8, 2022, 7:00 AM EST - 2 years ago

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:07 PM EST - 2 years ago

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 8, 2022, 6:13 PM EST - 2 years ago

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2022, 7:00 AM EST - 2 years ago

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 7, 2022, 8:59 AM EST - 2 years ago

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 2, 2022, 9:39 AM EDT - 2 years ago

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 5:30 PM EDT - 2 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 1:33 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 1, 2022, 10:50 AM EDT - 2 years ago

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials

Oct 31, 2022, 8:52 AM EDT - 2 years ago

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

Oct 31, 2022, 7:00 AM EDT - 2 years ago

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer

Oct 18, 2022, 7:00 AM EDT - 2 years ago

Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer

Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

Sep 19, 2022, 7:20 AM EDT - 3 years ago

Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

Doozio
Doozio Jun. 24 at 4:41 AM
Wait $TIL Roger see’s that comp rating to da monthly
0 · Reply
deezycvsh
deezycvsh Jun. 13 at 3:06 PM
$TIL What happened to this stock today
1 · Reply
Bigmal1
Bigmal1 Jun. 11 at 2:40 PM
$TIL institutions must be loading at the volume it’s been going
1 · Reply
_www_larval_com_
_www_larval_com_ Jun. 10 at 7:57 PM
$BIYA -8%[-48%] $EDHL 5%[10%] $BIRD -4%[20%] $TGE 4%[-9%] $TIL -3%[7%] most notable movement into the final minutes of trading.
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 5:22 PM
$TIL Keep going and split this stock!
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 4:49 PM
$TIL Oh now thats a tingle....
0 · Reply
BlakeCanyon50
BlakeCanyon50 Jun. 10 at 3:57 PM
$TIL +32% Later
1 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 10 at 1:02 PM
$TIL Needs to be north of $40 for me to take seriously!!!
1 · Reply
Bigmal1
Bigmal1 Jun. 9 at 2:28 PM
$TIL get through $35 and we see $100
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 7 at 1:32 PM
$TIL $GLYC ticker will change to CBIO with approx 25M fd shares OS at $20PS. Double the market cap of $TIL
0 · Reply
Bigmal1
Bigmal1 Jun. 6 at 2:41 PM
$TIL the 1 month chart looks amazing
0 · Reply
BlakeCanyon50
BlakeCanyon50 Jun. 5 at 5:28 PM
$TIL Worth Noting…
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 5 at 4:45 PM
$TIL HCW to Buy from Market Perform. PT unchanged
0 · Reply
JarvisFlow
JarvisFlow Jun. 5 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Instil Bio ( $TIL ), setting the rating to Buy with a target price of 125.
0 · Reply
risingofmars
risingofmars Jun. 4 at 8:05 PM
$TIL
0 · Reply
BlakeCanyon50
BlakeCanyon50 Jun. 3 at 12:31 AM
$TIL Mysterious little bio. Made a nice chunk in a week’s time or so. I’m not clear about their cash position so I sold today.
1 · Reply
QuiverQuant
QuiverQuant Jun. 2 at 7:46 PM
Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development. Read more about $TIL: https://www.quiverquant.com/news/Instil+Bio%2C+Inc.+Appoints+Jamie+Freedman%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+to+Propel+Cancer+Therapy+Development
0 · Reply
JarvisFlow
JarvisFlow Jun. 2 at 3:36 PM
JMP Securities updates rating for Instil Bio ( $TIL ) to Market Perform.
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 2 at 3:23 PM
$TIL just turned -5% lower to 21% (~620Kv) a few minutes ago, follow for more volatility.
0 · Reply
iamMoab
iamMoab Jun. 2 at 2:26 PM
$TIL back to $50 🙄
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 2 at 1:14 PM
$TIL Shorts are toast
1 · Reply